KYMR Key Statistics, Chart & Performance
The current stock price of KYMR is 67.88 USD. In the past month the price increased by 13.04%. In the past year, price increased by 44.85%.
KYMR Latest News, Press Relases and Analysis
KYMR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.25B | ||
| AMGN | AMGEN INC | 15.8 | 185.98B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 111.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.15B | ||
| INSM | INSMED INC | N/A | 43.92B | ||
| NTRA | NATERA INC | N/A | 32.78B | ||
| BIIB | BIOGEN INC | 10.88 | 26.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 21.98B | ||
| INCY | INCYTE CORP | 16.27 | 20.40B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About KYMR
Company Profile
Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company is headquartered in Watertown, Massachusetts and currently employs 218 full-time employees. The company went IPO on 2020-08-21. The firm is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The firm's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. The company is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. The company is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.
Company Info
KYMERA THERAPEUTICS INC
500 North Beacon Street, 4Th Floor
Watertown MASSACHUSETTS 02139 US
CEO: Nello Mainolfi
Employees: 218
Phone: 18572855314
KYMERA THERAPEUTICS INC / KYMR FAQ
Can you describe the business of KYMERA THERAPEUTICS INC?
Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company is headquartered in Watertown, Massachusetts and currently employs 218 full-time employees. The company went IPO on 2020-08-21. The firm is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The firm's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. The company is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. The company is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.
What is the current price of KYMR stock?
The current stock price of KYMR is 67.88 USD. The price increased by 0.03% in the last trading session.
What is the dividend status of KYMERA THERAPEUTICS INC?
KYMR does not pay a dividend.
How is the ChartMill rating for KYMERA THERAPEUTICS INC?
KYMR has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for KYMR stock?
29 analysts have analysed KYMR and the average price target is 77.71 USD. This implies a price increase of 14.47% is expected in the next year compared to the current price of 67.88.
Is KYMERA THERAPEUTICS INC (KYMR) expected to grow?
The Revenue of KYMERA THERAPEUTICS INC (KYMR) is expected to grow by 45.23% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the ownership structure of KYMERA THERAPEUTICS INC (KYMR)?
You can find the ownership structure of KYMERA THERAPEUTICS INC (KYMR) on the Ownership tab.
KYMR Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to KYMR. When comparing the yearly performance of all stocks, KYMR is one of the better performing stocks in the market, outperforming 94.03% of all stocks.
KYMR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KYMR. KYMR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
KYMR Financial Highlights
Over the last trailing twelve months KYMR reported a non-GAAP Earnings per Share(EPS) of -3.59. The EPS decreased by -58.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.78% | ||
| ROE | -31.19% | ||
| Debt/Equity | 0 |
KYMR Forecast & Estimates
29 analysts have analysed KYMR and the average price target is 77.71 USD. This implies a price increase of 14.47% is expected in the next year compared to the current price of 67.88.
For the next year, analysts expect an EPS growth of -19.72% and a revenue growth 45.23% for KYMR